Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.

BRCA1 or BRCA2 inactivation drives breast and ovarian cancer but also creates vulnerability to poly(ADP-ribose) polymerase (PARP) inhibitors. To search for additional targets whose inhibition is synthetically lethal in BRCA2-deficient backgrounds, we screened two pairs of BRCA2 isogenic cell lines with DNA-repair-focused small hairpin RNA (shRNA) and CRISPR (clustered regularly ...
interspaced short palindromic repeats)-based libraries. We found that BRCA2-deficient cells are selectively dependent on multiple pathways including base excision repair, ATR signaling, and splicing. We identified APEX2 and FEN1 as synthetic lethal genes with both BRCA1 and BRCA2 loss of function. BRCA2-deficient cells require the apurinic endonuclease activity and the PCNA-binding domain of Ape2 (APEX2), but not Ape1 (APEX1). Furthermore, BRCA2-deficient cells require the 5' flap endonuclease but not the 5'-3' exonuclease activity of Fen1, and chemically inhibiting Fen1 selectively targets BRCA-deficient cells. Finally, we developed a microhomology-mediated end-joining (MMEJ) reporter and showed that Fen1 participates in MMEJ, underscoring the importance of MMEJ as a collateral repair pathway in the context of homologous recombination (HR) deficiency.
Mesh Terms:
Ataxia Telangiectasia Mutated Proteins, BRCA1 Protein, BRCA2 Protein, CRISPR-Cas Systems, Cell Death, Cell Line, Tumor, DNA Damage, DNA End-Joining Repair, DNA-(Apurinic or Apyrimidinic Site) Lyase, Endonucleases, Flap Endonucleases, Gene Expression Regulation, Neoplastic, Genes, Lethal, Humans, Multifunctional Enzymes, Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Proliferating Cell Nuclear Antigen, Protein Binding, Protein Interaction Domains and Motifs, RNA Interference, RNA, Small Interfering, Synthetic Lethal Mutations
Mol Cell
Date: Mar. 07, 2019
Download Curated Data For This Publication
248139
Switch View:
  • Interactions 163